Siemens Healthineers received European approval for a blood test designed to help predict the risk of recurrence among patients with relapsing multiple sclerosis.
Right when testmakers began scaling back production in mid-2021, highly contagious variants of the virus swept in and surmounted the protections of COVID vaccines, sending diagnostic demand skyrocketing. And even as sales have once again taken a nosedive this year and developers have kept their forecasts conservative, they continue to post higher-than-expected numbers for the segment.
SUNNYVALE, Calif., June 30, 2022 (GLOBE NEWSWIRE) -- Intuitive (Nasdaq: ISRG), a global technology leader in minimally invasive care and the pioneer of robotic-assisted surgery, today announced the...
Triastek, Inc. and Siemens Ltd., China have signed a collaboration agreement to provide digital technologies for the global pharmaceutical industry. Combining Triastek's 3D printing and digital pharmaceutical technologies and Siemens' expertise in automation and digitization is expected to lead to innovative and transformative solutions for the development and manufacturing of pharmaceuticals.
The U.S. faces weeks of COVID-19 test shortages as the fast-growing omicron wave continues to outpace capacity, despite President Biden's plans for free at-home kits and the recent FDA authorization of over-the-counter tests made by Roche and Siemens Healthineers.
FDA granted breakthrough device status to Varian's Embozene microspheres in the treatment of symptomatic knee osteoarthritis. The microspheres, which are already used to treat some cancers and other diseases, are injected into the artery in the knee to drive embolization. By blocking up the vessel, the microspheres are designed to reduce blood flow to the affected region and thereby limit the inflammatory process and pain.
Merck KGaA, Darmstadt, Germany, a leading science and technology company, and Siemens, an innovation leader in automation and digitalization, Germany, plan to develop and implement solutions that offer unprecedented levels of digital trust in M2M connected industrial value chains. This would help industrial customers to comply with stricter regulations in the value chain in different countries and enable disruptive business models in a variety of industrial sectors, ranging from the food and beverage, pharmaceuticals and electronics industries to the automotive industry.
Though it is predicted to become a top cause of organ damage and liver transplants within this decade, treatments for non-alcoholic fatty liver disease, or NAFLD, have stalled for a simple reason: It can be hard to tell who has the condition and who does not.
Germany, France and Israel will go ahead with plans to administer COVID-19 vaccine boosters, disregarding an appeal by the World Health Organisation to hold off until more people are vaccinated around the world.
Flywheel and Siemens Healthineers Partner for Healthcare Research Collaboration